These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25467023)

  • 21. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
    Elit L
    IDrugs; 2006 Sep; 9(9):636-44. PubMed ID: 16952072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O
    Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anticancer drug dose individualisation: from body surface area to physiology].
    Pétain A; Chatelut E
    Bull Cancer; 2008 Oct; 95(10):895-901. PubMed ID: 19004718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of individualized dosing in oncology: are we there yet?].
    Joerger M
    Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 30. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP; Hug B; Leister C; Sonnichsen D
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
    Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.
    Ferrer F; Tetu P; Dousset L; Lebbe C; Ciccolini J; Combarel D; Meyer N; Paci A; Bouchet S
    Crit Rev Oncol Hematol; 2024 Aug; 200():104385. PubMed ID: 38810843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
    Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
    Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Takasaki S; Tanaka M; Kikuchi M; Maekawa M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    Biomed Chromatogr; 2018 Jun; 32(6):e4184. PubMed ID: 29283445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interaction between pazopanib and cisplatin regimen.
    Imbs DC; Diéras V; Bachelot T; Campone M; Isambert N; Joly F; Jimenez M; Lafont T; Chatelut E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):385-92. PubMed ID: 26779916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.